Monogram

With an ever-increasing number of options for diagnostic sequencing, the decision of whether to do a gene panel, exome, or whole genome becomes complicated.

When inking companion diagnostic deals with drug developers, most test makers are trying to get beyond fee-for-service arrangements and strike more creative agreements with potential for bigger profits over a longer period of time.

Quest Diagnostics has published a validation study of its laboratory-developed HIV tropism test that uses a combination of Sanger sequencing and next-generation sequencing on Roche's 454 GS Junior platform.